Cowen Healthcare Investments — Full Portfolio
18 tracked investments · listed companies and verified rows first
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)inKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)inPaul L. Feldman(Chief Scientific Officer)in
Co-investorsAndreessen HorowitzEcoR1 CapitalMPM BioImpactMRL Ventures FundPappas CapitalRA Capital+5 more
Company developing molecules targeting a novel class of receptors for neuro-immuno-inflammatory diseases; acquired by Incyte in May 2024.
BiotechSan Diego, US
Alain Baron(Founder)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Founder)
BoardAndrew Schwab(Director)in
Board seatKevin Raidy· per SEC Form D · $120M raise · filed Nov 2022
Co-investors5AM VenturesAvego BioScience CapitalNew Enterprise Associates (NEA)OUP (Osage University Partners)Sanofi VenturesThe Column Group+2 more
Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing.
BiotechHealthtechBrookline, US
Emmanuel Simons(Executive Officer, Director)william sewell(Founder)in
BoardEd Mathers(Director)inKush Parmar(Director)in
Co-investors5AM VenturesEcoR1 CapitalNew Enterprise Associates (NEA)Pivotal Life SciencesRA CapitalSofinnova Ventures+2 more
Aro is a Brazilian technology platform that connects users with over 40 regulated credit partners to find personal loans, payroll (consignado CLT) loans, phone-collateral loans, and credit for people with negative credit records.
AI & Machine LearningB2B MarketplacesFintech
Co-investorsNorte VenturesOnevc Venture Partners Llc17SigmaNorthpond Ventures
Aro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins.
BiotechHealthtechPhiladelphia, US
Karyn O'Neil(Executive Officer, Director)Susan Dillon(Founder)inMark V. Laurenzi(Executive Officer)
BoardElizabeth Anderson(Director)Bruce Peacock(Director)
Co-investorsAvego BioScience CapitalHealthCapAgent CapitalBiotechnology Value FundJohnson & Johnson Innovation – JJDCNorthpond Ventures
Cadent Therapeutics was a Cambridge, Massachusetts-based neuroscience company developing clinical-stage therapies for neuropsychiatric disorders including schizophrenia, movement disorders, and treatment-resistant depression.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Co-investorsClal Biotechnology IndustriesQiming Venture Partners USASlater Technology FundAccess IndustriesAtlas VentureNovartis Institute for Biomedical Research+1 more
Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases.
BiotechDeep Tech
Co-investorsGV (Google Ventures)OrbiMedOxford Science EnterprisesPanacea VentureREDMILE
Kezar Life Sciences is a clinical-stage biotechnology company developing small-molecule therapeutics for immune-mediated diseases and cancer.
BiotechSouth San Francisco, US
John F. Fowler(Executive Officer, Director)inChristopher J. Kirk(Executive Officer, Director)
BoardDr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)
Co-investorsBay City CapitalChiesi VenturesPappas CapitalQiming Venture Partners USASolasta VenturesEcoR1 Capital+1 more
KSQ Therapeutics develops eTIL therapies—engineered tumor-infiltrating lymphocyte treatments for solid tumors—using its proprietary CRISPRomics platform to identify and target novel therapeutic candidates through genome-wide CRISPR/Cas9 functional genomic screens.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Tim Wang(Cofounder)JOHN TRZUPEK, PH.D.(TREASURER, SECRETARY & CHIEF FINANCIAL OFFICER)DAVID P. MEEKER, M.D.(PRESIDENT AND CHIEF EXECUTIVE OFFICER)inFRANK STEGMEIER, PH.D.(CHIEF SCIENTIFIC OFFICER)Qasim Rizvi(Chief Executive Officer)inJAMES GILBERT(Director)
Co-investorsAlpha Wave GlobalARCH Venture PartnersFlagship PioneeringLAVLG Technology VenturesLilly Asia Ventures+3 more
Nested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology.
AI & Machine LearningBiotechHealthtech
Arvin Dar(Co-founder & Board Observer)inKevan Shokat(Scientific Co-founder)Klaus Hoeflich(Co-founder & former Chief Scientific Officer)inDarrin Miles(Chief Executive Officer)inPhilip Komarnitsky(Chief Medical Officer)inTanja Weber(Chief Business Officer)in
Co-investorsVersant VenturesForesite CapitalSixty Degree CapitalGoldman SachsSection 32
Neuron23 is a biotech company using data science, human genetics, and functional genomics to develop precision medicines and companion diagnostics for neurodegenerative diseases, starting with an LRRK2 program for Parkinson's disease.
AI & Machine LearningBiotechDeep TechDigital HealthSouth San Francisco, US
Nancy Stagliano(CEO)in
Co-investorsHBM Healthcare InvestmentsHBM PartnersKleiner PerkinsSoftBank GroupSoftBank Vision FundWestlake Village BioPartners+2 more
Cambridge, US
Christophe Queva(Executive Officer)inTheodore Ashburn(Executive Officer, Director)Alon Lazarus(Director)Cameron Wheeler(Director)in
BoardBriggs Morrison(Director)inMitchell Finer(Executive Officer, Director)
Co-investorsAstellas Venture Management LLCIMM Investment JapanDeerfield Management CompanyIMM InvestmentK2 HealthVenturesMPM BioImpact+1 more
Orchard Therapeutics develops ex vivo autologous hematopoietic stem cell (HSC) gene therapies for genetic and other severe diseases, including rare inherited conditions such as ADA-SCID and metachromatic leukodystrophy.
BiotechDeep TechHealthtechMedical DevicesLondon, GB
Donald Kohn(Scientific Founder)Adrian Thrasher(Scientific Founder)Frank E. Thomas(Executive Officer)inSteven M. Altschuler(Director)John Curnutte(Director)
BoardBobby Gaspar(Scientific Founder)in
Co-investorsAlbionVCF-Prime CapitalForesite CapitalUCL Technology Fund4BIO CapitalAgent Capital+3 more
Cambridge, MA biotech developing stem cell-derived islet therapy plus an immune-protective device for type 1 diabetes; acquired by Vertex for $950M.
BiotechCambridge, US
Robert Millman(Executive Officer, Director)
BoardTodd Foley(Executive Officer, Director)inMitch Finer(Director)Stephen Knight(Director)inJim Scopa(Director)William Sahlman(Director)
Co-investorsARCH Venture PartnersF-Prime CapitalJDRF T1D FundORI CapitalSlater Technology Fund6 Dimensions Capital+4 more
Star Therapeutics develops treatments aimed at addressing real-world patient needs.
BiotechSouth San Francisco, US
Adam Rosenthal(Founder & CEO)inNancy Stagliano(Director)inMichelle Carpenter(Executive Officer)Sandip Panicker(Executive Officer)Scott Robertson(Executive Officer)inGary Patou(Executive Officer)in
Co-investorsFrazier Life SciencesOrbiMedRA CapitalSanofi VenturesSofinnova VenturesViking Global+11 more
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
BiotechCambridge, US
Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)
Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalAlexandriaAlly Bridge GroupBain Capital+11 more
TORL BioTherapeutics develops antibody-drug conjugates (ADCs) targeting Claudin 6 (CLDN6) for the treatment of solid tumors such as ovarian, lung, endometrial, and testicular cancers.
BiotechHealthtechCulver City, US
Dave LicatainAran Maree M.D.inMark Alles(Executive Officer, Director)Mark Attanasio(Director)David Licata(Executive Officer, Director)Neil O'Brien(Director)
Co-investorsOCV PartnersRA CapitalGoldman SachsPerceptive Xontogeny VentureVertex Ventures HC
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.






































































